Vimarsana
Biggest News Aggregation in the World

Page 2 - Allogene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Allogene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Allogene Today - Breaking & Trending Today

Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022 - Vimarsana News

Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 27, 2022 -- Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the... | April 27, 2022

Biopharma charts progress in translating CAR-T cell therapies to solid cancers - Vimarsana News

Biopharma charts progress in translating CAR-T cell therapies to solid cancers

Several startups are raising interest—and dollars—to support innovative strategies for developing cell therapies to treat solid tumors. But their task is far from easy, with a combination of logistical hurdles and safety issues threatening to slow their progress.

Bristol Myers Squibb-backed Clade nabs a meaty $87M series A for cell therapy 2.0 - Vimarsana News

Bristol Myers Squibb-backed Clade nabs a meaty $87M series A for cell therapy 2.0

It still feels as if the use of cell therapy is a fresh innovation, but inertia is the enemy of progress, and next-gen approaches are already here.

Allogene Therapeutics Drops Premarket After FDA Puts Hold on Study - Vimarsana News

Allogene Therapeutics Drops Premarket After FDA Puts Hold on Study

By Chris Wack Allogene Therapeutics Inc. shares fell 38% to $15 in premarket trading after the company said the U.S. Food and Drug Administration put a hold on AlloCAR T clinical trials... | October 8, 2021

ALLOGENE THERAPEUTICS, INC. : Other Events (form 8-K) - Vimarsana News

ALLOGENE THERAPEUTICS, INC. : Other Events (form 8-K)

Item 8.01 Other Events. On October 7, 2021, Allogene Therapeutics, Inc. reported that, following a report of a chromosomal abnormality in ALLO-501A chimeric antigen receptor T cells in a patient... | October 8, 2021